96 related articles for article (PubMed ID: 23394441)
1. Glargine safety, diabetes and cancer.
Rendell M; Akturk HK; Tella SH
Expert Opin Drug Saf; 2013 Mar; 12(2):247-63. PubMed ID: 23394441
[TBL] [Abstract][Full Text] [Related]
2. ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use.
Lombard L; Distiller L; Aalbers J
Cardiovasc J Afr; 2012 Jul; 23(6):357-8. PubMed ID: 23091824
[No Abstract] [Full Text] [Related]
3. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
[TBL] [Abstract][Full Text] [Related]
4. Diabetes mellitus and the risk of cancer.
Pandey A; Forte V; Abdallah M; Alickaj A; Mahmud S; Asad S; McFarlane SI
Minerva Endocrinol; 2011 Sep; 36(3):187-209. PubMed ID: 22019750
[TBL] [Abstract][Full Text] [Related]
5. [Diabetes, insulin, insulin analogues, and cancer].
Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU
Dtsch Med Wochenschr; 2010 May; 135(18):924-9. PubMed ID: 20425680
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
7. [What has the largest study in the history of diabetology brought us?].
Rusavý Z; Lacigová S; Kvapil M
Vnitr Lek; 2013 Mar; 59(3):160-4. PubMed ID: 23713181
[TBL] [Abstract][Full Text] [Related]
8. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
Diabetologia; 2012 Jan; 55(1):51-62. PubMed ID: 21956710
[TBL] [Abstract][Full Text] [Related]
9. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
[TBL] [Abstract][Full Text] [Related]
10. Early insulin treatment in type 2 diabetes: ORIGINal sin or valuable choice as ORIGINal treatment? An open debate on the ORIGIN study results.
Bolli GB; Consoli A; Giaccari A
Nutr Metab Cardiovasc Dis; 2012 Dec; 22(12):1007-12. PubMed ID: 23199612
[TBL] [Abstract][Full Text] [Related]
11. Insulin detemir (levemir), a new long-acting insulin.
Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
[TBL] [Abstract][Full Text] [Related]
12. Cancer risk in diabetic patients treated with insulin glargine?
Prescrire Int; 2010 Aug; 19(108):162-3. PubMed ID: 20939447
[TBL] [Abstract][Full Text] [Related]
13. Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.
Juhaeri J; Gao S; Dai WS
Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):497-503. PubMed ID: 19326365
[TBL] [Abstract][Full Text] [Related]
14. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
Edwards KL; Riche DM; Stroup JS; Goldman-Levine JD; Padiyara RS; Cross LB; Kane MP
Pharmacotherapy; 2010 Sep; 30(9):955-65. PubMed ID: 20795850
[TBL] [Abstract][Full Text] [Related]
15. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes.
Lind M; Fahlén M; Eliasson B; Odén A
Prim Care Diabetes; 2012 Apr; 6(1):53-9. PubMed ID: 22056422
[TBL] [Abstract][Full Text] [Related]
16. Diabetes, antihyperglycemic medications and cancer risk: smoke or fire?
Gallagher EJ; LeRoith D
Curr Opin Endocrinol Diabetes Obes; 2013 Oct; 20(5):485-94. PubMed ID: 23974779
[TBL] [Abstract][Full Text] [Related]
17. Risk of cancer in patients receiving insulin glargine.
Dawson LK; Hamilton LA
Am J Health Syst Pharm; 2010 Dec; 67(23):2025-31. PubMed ID: 21098374
[TBL] [Abstract][Full Text] [Related]
18. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.
Pawaskar M; Li Q; Reynolds MW
Curr Med Res Opin; 2012 Jun; 28(6):991-7. PubMed ID: 22519390
[TBL] [Abstract][Full Text] [Related]
19. Hypoglycemia rates with basal insulin analogs.
Little S; Shaw J; Home P
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]